MedTrace Logo

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

NCT00604409 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2015-09-07

No results posted yet for this study

Summary

This trial is testing the safety of combining the oral chemotherapy drug capecitabine with radio-labeled microspheres injected directly into the liver.

Conditions

  • Metastatic Liver Cancer

Interventions

RADIATION

SIRT

Undergo SIRT

DRUG

capecitabine

Given PO

Sponsors & Collaborators

  • Sirtex Medical

    collaborator INDUSTRY

  • Fox Chase Cancer Center

    lead OTHER

Principal Investigators

  • Steven J. Cohen, M.D. · Fox Chase Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2014-06-30
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604409 on ClinicalTrials.gov